BridgeBio Pharma (BBIO) Invested Capital (2018 - 2026)

BridgeBio Pharma (BBIO) reported Invested Capital of $547.5 million for Q1 2026, down 26.76% sequentially from $747.5 million in Q3 2021.

BridgeBio Pharma (BBIO) Invested Capital (2018 - 2026) Analysis & Trends

BridgeBio Pharma (BBIO) has 5 years of Invested Capital data on file, last reported at $547.5 million in Q1 2026.

For the quarter ending Q1 2026, Invested Capital changed N/A year-over-year to $547.5 million; the trailing twelve-month figure through Mar 2026 stood at $547.5 million (changed N/A YoY), and the FY2020 full-year result was $550.0 million, up 3316.15% from the prior year.
Invested Capital eased to $547.5 million in Q1 2026, from $747.5 million in the prior quarter.
In the past five years, Invested Capital ranged from a high of $547.5 million in Q1 2026 to a low of $547.5 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	110.96 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	116.14 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	BridgeBio Pharma	16.15 Bn	15.22 Bn	184.58 Mn	547.48 Mn

Download Data